Lundbeck Accelerates AI Integration by Appointing New Chief AI Officer

Lundbeck Accelerates AI Integration with New Leadership

On March 10, 2026, H. Lundbeck A/S welcomed Markus Kede as its Senior Vice President and Chief AI Officer, marking a significant advancement in the company's evolving strategy towards incorporating artificial intelligence into its operations. This appointment represents a crucial part of Lundbeck's ambition to become a bionic company, enhancing their approach to research and patient care.

Charl van Zyl, President and CEO of Lundbeck, emphasized the importance of AI, stating that it transcends mere technological upgrades. Instead, it reflects a shift in how Lundbeck views decision-making and operational execution throughout its value chain. The company envisions AI as a transformative force, enabling it to operate more efficiently and effectively.

As Lundbeck progresses in its Focused Innovator strategy, AI stands out as a pivotal component in redefining how they innovate and scale patient impact. Kede's extensive background, including over 15 years of international leadership in highly regulated environments, positions him uniquely to lead this initiative. Before his new role, he served as Senior Vice President of Finance and Business Planning for Lundbeck US, where he demonstrated his capability to enhance AI initiatives that promote enterprise-level adoption of technology.

Kede's chief responsibilities will involve steering the global AI strategy of Lundbeck towards its ultimate goals. This includes establishing robust governance structures for AI practices and facilitating the growth of AI capabilities across various functions within the company. His objective is to ensure that the integration of AI delivers measurable value, thereby enhancing Lundbeck's competitiveness in the long term.

Recent collaborations with leading AI organizations, such as OpenAI and the Danish Centre for AI Innovation, have already fortified Lundbeck’s commitment to leveraging AI in research and commercial applications. These partnerships are designed to enrich the process of discovering new drug candidates and elevate patient support through improved customer engagement.

As Kede prepares to transition into his new role by July 1, he is expected to further solidify Lundbeck’s strategic ambitions in revolutionizing healthcare solutions through intelligent systems. His leadership promises to guide the effective deployment of AI solutions that prioritize value creation and operational excellence.

Lundbeck continues to enhance its standing as a biopharmaceutical leader focused on brain health, evolving its portfolio to address the pressing needs associated with neurological and psychiatric diseases. With over 5,000 employees across 20 countries, Lundbeck remains dedicated to innovating solutions that meet the complex challenges posed by brain disorders, striving for health equity and improved patient outcomes.

As the world observes rapid advancements in neuroscience, the integration of AI into Lundbeck's operations heralds a promising era where innovation meets compassionate healthcare, ultimately aiming to benefit patients, their families, and society at large.